



lisinopril ICI

Prescribing Notes.

Consult data sheet before prescribing.

Use: All grades of essential hypertension and renovascular hypertension. Congestive heart failure (adjunctive therapy).

Presentation: Tablets containing 2.5mg, 5mg, 10mg or 20mg lisinopril ('Zestril').

Dosage and administration:
Hypertension - initially 2.5mg daily, a 2.5mg dose seldom achieves a therapeutic response; adjust dose according to response. Maintenance usually 10-20mg once daily. Maximum is 40mg daily. Diuretic-treated patients - if possible stop diuretic 2-3 days before starting 'Zestril'. Resume diuretic later if desired.

Congestive heart failure: (adjunctive therapy) - initially 2.5mg daily in hospital under close medical supervision, increasing to 5-20mg once daily according to response.

Impaired renal function: May require a lower maintenance dose. 'Zestril' is dialysable.

Elderly patients: No change from standard recommendations.

Contraindications: Pregnancy - stop therapy if suspected. Hypersensitivity to 'Zestril'. Patients reacting with angioneurotic oedema to previous ACE inhibitor treatment.

Precautions: Assessment of renal function is recommended. Renal insufficiency; renovascular hypertension; surgery/anaesthesia; possibility of hypotension especially in ischaemic heart disease and cerebrovascular disease. Combination with antihypertensives may increase hypotensive effect. Sometimes increased blood urea and creatinine and/or cases of renal insufficiency if given with diuretics. Mimises thiazide-induced hypokalaemia and hyperuricaemia. Potassium supplements, potassium-sparing diuretics and potassium-containing salt substitutes not recommended. Indomethacin may reduce hypotensive effect. Possible reduced response in Afro-Caribbean patients. Use with caution in breastfeeding mothers. Do not use in aortic stenosis or outflow tract obstruction or cor pulmonale. Monitor lithium serum levels if lithium salts administered.

Side effects: Dizziness, headache, diarrhoea, fatigue, cough and nausea. Less frequently, rash and asthenia. Rarely, angioneurotic oedema and other hypersensitivity reactions; renal failure; symptomatic hypotension (especially if volume depleted); severe hypotension (more likely if severe heart failure); palpitation; hyperkalaemia; increases in liver enzymes and serum bilirubin (usually reversible on discontinuation of 'Zestril') and incoherence.

Product licence numbers and basic NHS cost: 'Zestril' 2.5mg (29/0208) 28 tablets, £7.84, 5mg (29/0204) 28 tablets, £9.83, 10mg (29/0205) 28 tablets, £12.13, 20mg (29/0206) 28 tablets, £20.96.

'Zestril' is a trademark. Further information is available from: ICI Pharmaceuticals (UK), Southbank, Alderley Park, Macclesfield, Cheshire SK10 4TF.



NOW
INDICATED
FOR
FIRST-LINE
ANTI-HYPERTENSIVE
THERAPY



Oh what a beautiful morning!

Everyone has a certain zest for life. 'Zestril' lets your hypertensive patients enjoy theirs. 'Zestril' is an effective ACE inhibitor from ICI. 'Zestril' is taken once daily, so encouraging good patient compliance. A valuable aspect of 'Zestril' therapy is that it is well

tolerated, and suitable for a wide range of hypertensive patients. Your hypertensive patients will appreciate the convenient dosage and good tolerability of 'Zestril'. It's a therapy they'll find easy to live with - one which helps retain their zest for life.

Morning, noon and night.

lisinopril ICI
Once daily for 24 hour BP control



Antihypertensive therapy which helps retain that zest for life.

Further information is available from: ICI Pharmaceuticals (UK), Southbank, Alderley Park, Macclesfield, Cheshire SK10 4TF.

H1324C NOV '90

Big idea



...this is the first true
sustained release formulation
of nifedipine*¹⁻²

NEW

CORACTEN SR

NIFEDIPINE 20 mg Sustained Release Capsules

Coracten abbreviated prescribing information

Presentation

'Coracten' Capsules, PL 0002/0159, each containing 20 mg nifedipine in sustained-release form. 100, £17.38.

Uses

Prophylactic treatment of angina pectoris; treatment of hypertension.

Dosage and administration

Adults only: Normally one capsule every 12 hours, increasing if necessary to 2 capsules every 12 hours.

Elderly: Although well tolerated, use with caution. Caution in patients with hepatic impairment. The capsules should be swallowed whole with a little fluid.

Contra-Indications

Hypersensitivity to nifedipine. Cardiogenic shock. Pregnancy or possible pregnancy.

Precautions

Hypotensive patients, those with poor cardiac reserve, diabetic patients,

dialysis patients with malignant hypertension and irreversible renal failure with hypovolaemia. If stopping previously prescribed β -blockers, withdraw gradually, preferably over 8 to 10 days. Bear in mind possibility of postural hypotension and/or cardiac failure if nifedipine is used with β -blockers or other antihypertensive agents. Rarely cardiac pain within 30 minutes of administration: stop treatment. Clinically insignificant increased plasma levels of nifedipine with H_2 -receptor antagonists. Bear in mind possibility of interaction with digoxin. With nifedipine, serum quinidine levels can be suppressed.

Use in pregnancy and lactation

'Coracten' contra-indicated during pregnancy; not recommended during lactation.

Adverse Reactions

Generally mild and transient, usually at start of treatment only. Headache, flushing, nausea, dyspepsia, heartburn, dizziness, lethargy, skin reactions, paraesthesia, hypotension, palpitation, tachycardia, dependent oedema. Very rarely allergic hepatitis, reversible gingival hyperplasia.

Overdosage

Symptoms: hypotension, also tachycardia or bradycardia. Treatment: gastric lavage then oral activated charcoal with supportive and symptomatic measures, principally IV fluids. If not sufficient, dopamine or dobutamine. Consider intravenous calcium gluconate.

Legal category

POM

1. Boulton J. Pharm J 1989; 242:180

2. Davis SS & Wilding JR. Nott. Univ. Data on File.

* Available in U.K.

Further information is available on request from:



Evans Medical Limited, Langhurst, Horsham, West Sussex, RH12 4QD.
'Coracten' is a trade mark © 1991 Evans Medical Limited